Day Gain | ||
Gain | ||
Market Val | ||
Costs | ||
Cash | ||
Portfolio | ||
Realized | ||
Dividend |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-07 | 2024-09 | 1.6 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | 1.34 | 1.4 | 0.06 | 4.48% |
2024-05-02 | 2024-03 | 1.51 | 1.53 | 0.02 | 1.32% |
2024-02-01 | 2023-12 | 2.09 | 2.18 | 0.09 | 4.31% |
2023-11-02 | 2023-09 | 1.39 | 1.46 | 0.07 | 5.04% |
2023-08-03 | 2023-06 | 1.19 | 1.26 | 0.07 | 5.88% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-10-31 | Wedbush | Upgrade | Outperform | Outperform |
2023-10-30 | Needham | Upgrade | Buy | Buy |
2023-10-29 | Keybanc | Upgrade | Sector Weight | |
2023-10-29 | Barclays | Upgrade | Equal-Weight | Equal-Weight |
2023-10-29 | Oppenheimer | Upgrade | Outperform | Outperform |
2023-10-23 | B of A Securities | Upgrade | Neutral | Neutral |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-08-06 | ADAMS KATHERINE L | General Counsel | 187.04K | Stock Gift |
2024-04-01 | COOK TIMOTHY D | Chief Executive Officer | 3.28M | Sale |
2024-01-31 | JUNG ANDREA | Director | 74.49K | Conversion of Exercise of derivative security |
2024-08-14 | KONDO CHRISTOPHER | Officer | 15.42K | Sale |
2024-05-29 | LEVINSON ARTHUR D | Director | 4.42M | Sale |
2024-04-10 | MAESTRI LUCA | Chief Financial Officer | 107.79K | Sale |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 1.30B | 252.88B | 8.34% |
2023-06-29 | Blackrock Inc. | 1.04B | 201.66B | 6.65% |
2023-06-29 | Berkshire Hathaway, Inc | 915.56M | 177.59B | 5.86% |
2023-06-29 | State Street Corporation | 578.90M | 112.29B | 3.70% |
2023-06-29 | FMR, LLC | 307.07M | 59.56B | 1.96% |
2023-06-29 | Geode Capital Management, LLC | 291.54M | 56.55B | 1.86% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 465.99M | 90.39B | 2.98% |
2023-06-29 | Vanguard 500 Index Fund | 352.02M | 68.28B | 2.25% |
2023-08-30 | Fidelity 500 Index Fund | 169.38M | 31.82B | 1.08% |
2023-09-29 | SPDR S&P 500 ETF Trust | 165.19M | 28.28B | 1.06% |
2023-09-29 | iShares Core S&P 500 ETF | 138.98M | 23.80B | 0.89% |
2023-06-29 | Vanguard Growth Index Fund | 127.13M | 24.66B | 0.81% |
Dividend | Date |
---|---|
0.25 | 2024-08-12 |
0.25 | 2024-05-10 |
0.24 | 2024-02-09 |
0.24 | 2023-11-10 |
0.24 | 2023-11-09 |
0.24 | 2023-08-14 |
Split | Date |
---|---|
4 : 1 | 2020-08-31 |
7 : 1 | 2014-06-09 |
2 : 1 | 2005-02-28 |
2 : 1 | 2000-06-21 |
2 : 1 | 1987-06-16 |
-
-
$FIRE is undervalue right now. Bought 1000
-
-
Go Apple up up new braking the icar Kia big money signing this month February great news Apple is firing on all cylinders again big step in to the Icar electric go Tim Cook
-
Go Apple go Apple up up slowly up up let’s see 150 eow yes . People don’t listen to the negativity of the short sellers . Buy buy the best company in the world and had their best quarter ever go Apple ,history repeats itself again and again up up Apple has a fantastic balance sheet fact are fact up up buy buy buy
-
-
Go Apple go Apple let’s see 150 eow or before yes up up money money up up 150 plus plus up up
-
Saphyr Study Is First to Analyze Cancer Regulation at Level of Single DNA Molecules, Opens Promising New Avenue of Cancer Research
Publication on novel Saphyr based method to analyze DNA methylation in cancer genomes enables new field of cancer research and drug target discovery
Bionano Genomics
February 02, 2021 08:00 ET
SAN DIEGO, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), announced today the publication of a study that measured DNA methylation, the chemical modification of the DNA that controls gene regulation, of the various regions regulating cancer genes on single DNA molecules. The study led by Dr. Yuval Ebenstein at the Tel Aviv University found that optical genome mapping (OGM) with Bionano’s Saphyr system combined with a custom labeling method developed by the scientists was capable of analyzing regulatory regions that work together to turn cancer genes on and off over distances of hundreds of thousands of basepairs. The ability to measure these relationships on single DNA molecules is something that was previously impossible. Only Saphyr can detect these long-distance connections in methylation profiles because it’s the only technology that can generate such long-range, single molecule data at high throughput and coverage.While most of the important information in our genome is encoded in the sequence and the structural organization of the sequence, the regulation of genes is partially registered through chemical labels attached to the DNA. These chemical labels, called DNA methylation, can turn genes on and off at specific time points and in certain tissues. A normal cell can only become cancerous and grow excessively by making multiple changes to the genome and the way it is regulated. These changes include single nucleotide variations, structural variations and changes to DNA methylation patterns that can happen to the actual cancer gene, to the promoter region that switches the gene on and off, or to enhancer regions that can be hundreds of thousands of basepairs removed from the cancer gene. Studying these methylation patterns has been difficult or impossible because current methods only allow you to measure values averaged over dozens or hundreds of cells. To fully understand how cancer genes are turned on and off, it is important to measure the methylation status of a gene, its promoter, and its enhancers on individual, single molecules, which is impossible with short-read or long-read sequencing because their read lengths are insufficient.
The study by Dr. Ebenstein is the first to systematically analyze more than one hundred thousand promoter-enhancer pairs up to 200,000 basepairs apart, on millions of single molecules. This large dataset enabled them to correctly distinguish between normal and tumor cells with an error rate smaller than 1%.
Yuval Ebenstein, PhD, commented: “Long methylation reads at such high coverage just never existed before, mostly because Saphyr produces the highest fraction of the longest reads compared to any other platform. This dataset allows us to analyze long range information on the single-molecule level, which opens up a whole new avenue for complex disease specific epigenetic biomarkers. This study can be dramatic for early cancer diagnostics where the normal and cancer cells have a very similar genetic background but the extreme changes in enhancer methylation distinguish the cancer cells. This data may for the first time allow us to discover new biomarkers and point to novel drug targets in places of the genome where no one has looked before.”
Erik Holmlin, PhD, CEO of Bionano Genomics commented: “While Bionano Genomics is laser focused on bringing comprehensive, whole genome structural variation detection to the clinic, scientists around the world are pushing the boundaries of what our single molecule analysis system Saphyr can do. Dr. Ebenstein’s team has developed a novel application of our technology that contributes to solving unique scientific questions. The epigenetic regulation of cancer genes through DNA methylation of its promoters and enhancers has been difficult or impossible to study with current methods that are limited by short read lengths. We are excited about the possibilities for discoveries of novel diagnostics and treatments for cancer that this application enables.”
The publication is available at https://www.biorxiv.org/content/10.1101/2021.01.28.428654v1
-
Go Apple up up let’s see 150 eow
-
-
Go Apple up up let’s see 150
-
Dynavax price target raised to $15 from $14 at H.C. Wainwright H.C. Wainwright analyst Edward White raised the firm's price target on Dynavax Technologies to $15 from $14 and reiterates a Buy rating on the shares. Dynavax and Clover Biopharmaceuticals this morning announced plans to initiate a global Phase 2/3 efficacy trial with Clover's S-trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum. CpG 1018 is the adjuvant used in Heplisav-B, Dynavax's marketed vaccine, White tells investors in a research note. The analyst reminds investors that Dynavax currently has five collaborations in place that are focused on developing COVID-19 vaccines. He estimates CpG 1018 adjuvant sales for COVID-19 vaccines of $100M in 2021
Read more at:
https://thefly.com/n.php?id=3238123 -
Go Apple go Apple let’s see 150 yes
-
Go Apple up up let’s see 150 yes
-
Buy the dips yes up up
-
Apple will soar this week well over sold , up up money money go Apple go Apple let’s see 150 plus yes go Apple go Apple
-
BASED ON THE LAST CRASH OF BITCOIN GOING FROM 20,000 to 3,500!!
THAT WOULD MEAN THAT THE NEXT CRASH FROM 40,000 should bottom out at 8,000$!!DO NOT HAVE A POSITION
JUST EXCITING TO WATCH.
GLTA. BE SAFE!! $BTC.X -
Let’s buy together
-
AAPL, NIO, CVS, STLA, TSLA: Top 5 Trending Stocks Today- Benzinga
news.google.com • -
Apple Stock Is Back Near Record High. New Phone Demand May Be a Factor.
news.google.com • -
Apple Stock Is Back Near Record High. New Phone Demand May Be a Factor.
news.google.com • -
Apple Stock Is Back Near Record High. New Phone Demand May Be a Factor.
news.google.com • -
Three Stocks: Apple, Nike, and Carnival
news.google.com • -
Apple Inc. stock outperforms competitors on strong trading day
news.google.com • -
10 Information Technology Stocks With Whale Alerts In Today's Session
news.google.com • -
Apple still well positioned for AI: Analyst
youtube.com • -
Why Apple (AAPL) stock is outperforming the market
finbold.com • -
David Shaw's Hedge Fund Is Buying These 3 Stocks
247wallst.com • -
Apple Inc (AAPL-Q) Quote- The Globe and Mail
news.google.com • -
Is Apple an Underrated Dividend Stock to Own?
news.google.com • -
Was Brad Gerstner Wrong About Apple’s (AAPL) AI Potential?
news.google.com • -
Apple Stock: Is It A Buy After iPhone 16 Sales Begin?
news.google.com • -
WT Asset Management Ltd Purchases New Shares in Apple Inc. (NASDAQ:AAPL)
news.google.com • -
APPLE INC : UBS reiterates its Neutral rating
news.google.com • -
iPhone 16 sees mixed sales response, but AAPL stock is going strong
news.google.com •
clickable symbol $AAPL
clickable link https://finabase.io/symbol/aapl